股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd
Total Page:16
File Type:pdf, Size:1020Kb
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. 上海復星醫藥(集團)股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (a joint stock limited company incorporated in the People’s Republic of China with limited liability) (Stock Code: 02196) SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO CONNECTED TRANSACTION Reference is made to the announcement of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “Company”) dated 28 December 2020 (the “Announcement”) in relation to, among others, the connected transaction in connection with the entering into the Xingjian Ruiying Partnership Agreement. Unless otherwise specified, capitalised terms used herein shall have the same meaning ascribed to them in the Announcement. The Company wishes to provide the Shareholders and the public with following additional information in relation to the Xinjian Ruiying Partnership Agreement. FURTHER INFORMATION ON THE RELEVANT PARTIES TO XINGJIAN RUIYING PARTNERSHIP AGREEMENT Supplemental information relating to the relevant parties to the Xingjiang Ruiying Partnership Agreement and their ultimate beneficial owners are set out below. Nanjing Industrial Development Fund The registered capital of Nanjing Industrial Development Fund is RMB10,000 million, the ultimate beneficial owner of Nanjing Industrial Development Fund is Nanjing Municipal People’s Government, and Nanjing Municipal People’s Government holds 100% of its equity interest. 1 Nanjing Yangtze River Fund The total contribution amount of Nanjing Yangtze River Fund is RMB3,003 million, of which approximately 99.9% interest is held by Nanjing Yang Zi State-owned Investment Group Co., Ltd.* (南 京揚子國資投資集團有限責任公司), and approximately 0.1% interest is held by Nanjing Yangtze River Investment Fund Management Co., Ltd.* (南京揚子江投資基金管理有限公司), being the executive partner of Nanjing Yangtze River Fund. The ultimate beneficial owner of Nanjing Yang Zi State-owned Investment Group Co., Ltd.* and Nanjing Yangtze River Investment Fund Management Co., Ltd.* is, and is wholly-owned by, Nanjing Jiangbei New Area Management Commission. Suzhou International Development Taicang Fund The total contribution amount of Suzhou International Development Taicang Fund is RMB101 million, of which approximately 99.01% interest is held by Taicang High-tech Investment Management Co., Ltd.* (太倉高新投資管理有限公司), and approximately 0.99% interest is held by Suzhou International Development Asset Management Co., Ltd.* (蘇州國發資產管理有限公司), being the executive partner of Suzhou International Development Taicang Fund. The ultimate beneficial owner of Taicang High-tech Investment Management Co., Ltd.* is, and is wholly-owned by, Jiangsu Taicang High-tech Industrial Development Zone Management Commission, and the ultimate beneficial owner of Suzhou International Development Asset Management Co., Ltd.* is, and is wholly-owned by, Suzhou State-owned Assets Management Commission. As disclosed in the Announcement, to the best of the Directors’ knowledge, information and belief, having made all reasonable enquiries, each of Nanjing Industrial Development Fund, Nanjing Yangtze River Fund and Suzhou International Development Taicang Fund and their respective ultimate beneficial owners are parties independent from the Company and its connected persons. By order of the Board Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Wu Yifang Chairman Shanghai, the PRC 31 December 2020 As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang. * for identification purposes only 2.